Neurogenic Detrusor OveractivityPhase 3NCT01981954
A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
A Phase 3 study testing Solifenacin succinate in people with Neurogenic Detrusor Overactivity and Pediatric, run by Astellas Pharma Europe B.V. at 8 sites in 6 countries.
Trial summary
The purpose of this study was to evaluate long term efficacy and safety of treatment with solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after multiple dose administration. Read more about this study
- Who is it for?
- Ages 6 months to 4 years
- Conditions the study is for
- Neurogenic Detrusor Overactivity, Pediatric
- What is being tested?
- Solifenacin succinate
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 23 participants
- Where
- 8 sitesin 6 countries
- Study dates
- 25 Sep 2013to 18 Dec 2015
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 4 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Myelomeningocoele
- Documented diagnosis of NDO, confirmed by urodynamics
- DSD (detrusor sphincter dyssynergia)
- Practicing clean intermittent catheterization (CIC)
Who cannot join
- Know genitourinary condition (other than NDO) that may cause incontinence
- Bladder augmentation surgery
- Current faecal impaction
- Electro-stimulation therapy within 2 weeks prior to visit
- Subjects with the following gastro-intestinal problems: partial or complete obstructions, decreased motility like paralytic ileus, subjects at risk of gastric retention
- Reflux grade 3 to 5
- Current urinary tract infection
Trial locations and contacts
8 sites in 6 countries.
8 sites in 6 countries
Poland2 sites
Site PL4803 Uniwersyteckie Centrum Kliniczne
Gdansk, 81-211
Site PL4801 Pomnik-Centrum Zdrowia Dziecka
Warsaw, 04-730
South Korea2 sites
Site KR8207 Seoul National University Hospital
Seoul, 110744
Site KR8201 Severance Hospital
Seoul, 120752
United States1 site
Site US1008 Pediatric Urology Associates, P.C.
Tarrytown, New York, 10591
Philippines1 site
Site PH6301 Philippines Children's Medical Center
Manila, 1015
United Kingdom1 site
Site GB4401 Sheffield Children's Hospital
Sheffield, S10 2TN
About this study
Official title: A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose-Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children From 6 Months to Less Than 5 Years of Age With Neurogenic Detrusor Overactivity
The purpose of this study was to evaluate long term efficacy and safety of treatment with solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after multiple dose administration.
Read the detailed description
In some children with a severe form of spina bifida (which is the consequence of a spinal cord defect), the bladder muscle (detrusor) contracts strongly and without warning (also known as neurogenic detrusor overactivity) and the urethra (the passage connecting the bladder with outside) does not relax. Though these children cannot void, urine leakage can happen when the overactive contractions are strong, and/or the pressure in the bladder is so high that it overcomes the closed urethra (overflow at high filling bladder pressure). This high bladder pressure puts these children at risk for kidney damage and can decrease the quality of the bladder. Therapy was aimed to decrease the high filling bladder pressure and the overactive detrusor contractions.
- Conditions
- Neurogenic Detrusor Overactivity, Pediatric
- Being tested
- Solifenacin succinate
- Keywords
- Solifenacin succinate suspension, Efficacy, Safety
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Solifenacin succinateDrug
Also called solifenacin, YM905, solifenacin succinate suspension
Oral suspension
| Study group | Role | What they receive |
|---|---|---|
| Solifenacin succinate | Experimental | Children aged 6 months to less than 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. Receives: Drug: Solifenacin succinate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC)
MCC was the volume instilled into the bladder prior to leakage or end of bladder-filling (whichever was reached first), as assessed by urodynamics (procedure: the bladder was to be filled until voiding/leakage began, or until it was stopped because either the participant experienced pain or discomfort or 135% of expected bladder capacity [EBC] was reached for participants ≥ 2 years or of maximum catheterized volume [MCV] for participants aged 6 months to < 2 years; the participants' bladder was emptied via catheterization).
Measured: Baseline and Week 24
Secondary outcomes (41)
Change From Baseline to Weeks 3, 6, 9, 12 and 52 in MCC
MCC was the volume instilled into the bladder prior to leakage or end of bladder-filling (whichever was reached first) as assessed by urodynamics (procedure: the bladder was to be filled until voiding/leakage began, or until it was stopped because either the participant experienced pain or discomfort or 135% of EBC was reached for participants ≥ 2 years or of MCV for participants aged 6 months to < 2 years. The participants' bladder was emptied via catheterization).
Measured: Baseline and Weeks 3, 6, 9, 12, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Compliance
Bladder compliance gives an indication of the elasticity of the bladder wall. Bladder compliance was calculated by dividing the change in volume during the filling of the bladder by the change in detrusor pressure during that change in bladder volume using urodynamic assessments. The values for bladder volume and detrusor pressure at the beginning and end of filling were taken and used.
Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Detrusor Pressure at End of Bladder-Filling
Detrusor pressure was expressed as bladder pressure minus intra-abdominal pressure as assessed by urodynamics.
Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Detrusor Pressure 5 Minutes After End of Bladder-Filling
Detrusor pressure was expressed as bladder pressure minus intra-abdominal pressure as assessed by urodynamics.
Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Catheterized Volume 5 Minutes After End of Bladder-Filling
Catheterized volume was measured when the bladder was emptied via catheterization 5 minutes after the end of bladder-filling.
Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume Until First Detrusor Contraction (> 15 cmH2O)
Bladder volume as assessed by urodynamics.
Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 10 cmH20 Detrusor Pressure
Bladder volume as assessed by urodynamics.
Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 20 cmH20 Detrusor Pressure
Bladder volume as assessed by urodynamics.
Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 30 cmH20 Detrusor Pressure
Bladder volume as assessed by urodynamics.
Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Number of Overactive Detrusor Contractions (> 15 cmH2O) Until Leakage or End of Bladder-Filling
Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Average Catheterized Volume Per Catheterization
The average catheterized volume per catheterization was calculated using all available (non-zero) catheterized volumes recorded over both of the 2 measuring days in the diary, whether or not these 2 days were concurrent. Catheterized volumes were recorded for 2 days in a participant diary prior to each visit. Four to six catheterizations were performed every day.
Measured: Baseline and Weeks 3, 6, 9, 12, 24, 36, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Maximum Catheterized Volume (MCV)
The maximum catheterized volume per day was calculated using all available (non-zero) catheterized volumes recorded for the 2 measuring days in the diary, whether or not these 2 days were concurrent. The maximum value was calculated separately for each measuring day and the mean of these two values was used.
Measured: Baseline and Weeks 3, 6, 9, 12, 24, 36, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Average First Morning Catheterized Volume
The first morning catheterized volume was the volume associated with the first morning catheterization. The average first morning catheterized volume was calculated as the average of the available first morning catheterized volumes recorded for the 2 measuring days in the diary, whether or not these 2 days are concurrent.
Measured: Baseline and Weeks 3, 6, 9, 12, 24, 36, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Mean Number of Periods Between the Clean Intermittent Catheterizations (CICs) With Incontinence Per 24 Hours
Participants were required to have 4-6 CICs per day on a schedule fixed for the duration of the study. To calculate the number of periods between CICs with incontinence in a diary day, the diary day was divided into periods between CICs (i.e. inter-CIC periods). The hour period, rather than the exact time, of each CIC and incontinence episode was recorded in the diary. When an incontinence episode and a CIC were marked in the same hour period, the incontinence episode was counted as occurring prior to the CIC (when the bladder had not yet emptied), rather than after it (when the bladder had recently been emptied), i.e. the inter-CIC period ended with the hour in which the CIC was recorded. The mean number of periods between CICs with incontinence per 24 hours was the number of periods between CICs when incontinence occurred, divided by the total number of valid diary days.
Measured: Baseline and Weeks 3, 6, 9, 12, 24, 36, 52
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day at Baseline
For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Baseline visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 3
For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 3 visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 6
For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 6 visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 9
For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 9 visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 12
For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 12 visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 24
For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 24 visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 36
For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 36 visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 52
For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all subjects. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 52 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day at Baseline
Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Baseline visit
Percentage of Days With of Incontinence for Each Hour of 24 Hour Day During Week 3
Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 3 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 6
Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 6 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 9
Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 9 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 12
Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 12 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 24
Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 24 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 36
Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 36 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 52
Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.
Measured: 3 days prior to Week 52 visit
Change From Baseline to Week 24 and 52 in Infant and Toddler Quality of Life Short Form-47 Questionnaire (ITQoL SF-47) - Overall Health Score
The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).
Measured: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Physical Abilities Score
The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).
Measured: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Growth and Development Score
The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).
Measured: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Pain Score
The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).
Measured: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Temperament and Moods Score
The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).
Measured: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Behaviour Score
The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).
Measured: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - General Health Score
The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).
Measured: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Change in Health Score
The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).
Measured: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Parent-Emotional Impact Score
The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).
Measured: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Parent-Time Impact Score
The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).
Measured: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Family Cohesion Impact Score
The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).
Measured: Baseline and Weeks 24, 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Nov 2013 (estimated)
- Study start25 Sep 2013
- Primary completion18 Dec 2015
- Study completion18 Dec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Neurogenic Detrusor OveractivityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 23 participants (actual)
Sponsor and investigators
- Lead sponsor
- Astellas Pharma Europe B.V.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Director, Study director, Astellas Pharma Europe B.V.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01981954
- Sponsor's protocol ID
- 905-CL-074
- Other IDs
- 2012-003178-22
- Status last verified
- Oct 2024
- First submitted
- 6 Nov 2013
- Last updated
- 31 Oct 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- No: Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Publications
Tannenbaum S, den Adel M, Krauwinkel W, Meijer J, Hollestein-Havelaar A, Verheggen F, Newgreen D. Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity. Pharmacol Res Perspect. 2020 Dec;8(6):e00684. doi: 10.1002/prp2.684.
PubMed 33231929Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E, Snijder R, Stroosma O, Verheggen F, Newgreen D, Bosman B, Vande Walle J. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies. J Pediatr Urol. 2020 Apr;16(2):180.e1-180.e8. doi: 10.1016/j.jpurol.2019.12.012. Epub 2019 Dec 27.
PubMed 32007426
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose-Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children From 6 Months to Less Than 5 Years of Age With Neurogenic Detrusor Overactivity
- ClinicalTrials.gov ID
- NCT01981954
- Acronym / sponsor ID
- 905-CL-074
- Conditions
- Neurogenic Detrusor Overactivity, Pediatric
- Keywords
- Solifenacin succinate suspension, Efficacy, Safety
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 23 participants (actual)
- Lead sponsor
- Astellas Pharma Europe B.V.Industry (pharma, biotech, devices)
- Study start
- 25 Sep 2013 (actual)
- Primary completion
- 18 Dec 2015 (actual)
- Study completion
- 18 Dec 2015 (actual)
- First posted
- 13 Nov 2013 (estimated)
- Results
- Posted 21 Jun 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to evaluate long term efficacy and safety of treatment with solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after multiple dose administration.
Detailed description
In some children with a severe form of spina bifida (which is the consequence of a spinal cord defect), the bladder muscle (detrusor) contracts strongly and without warning (also known as neurogenic detrusor overactivity) and the urethra (the passage connecting the bladder with outside) does not relax. Though these children cannot void, urine leakage can happen when the overactive contractions are strong, and/or the pressure in the bladder is so high that it overcomes the closed urethra (overflow at high filling bladder pressure). This high bladder pressure puts these children at risk for kidney damage and can decrease the quality of the bladder. Therapy was aimed to decrease the high filling bladder pressure and the overactive detrusor contractions.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Solifenacin succinate | Experimental | Drug: Solifenacin succinateChildren aged 6 months to less than 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
Who may qualify
- Ages
- 6 months to 4 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Myelomeningocoele
- Documented diagnosis of NDO, confirmed by urodynamics
- DSD (detrusor sphincter dyssynergia)
- Practicing clean intermittent catheterization (CIC)
Key exclusion criteria (7 listed)
- Know genitourinary condition (other than NDO) that may cause incontinence
- Bladder augmentation surgery
- Current faecal impaction
- Electro-stimulation therapy within 2 weeks prior to visit
- Subjects with the following gastro-intestinal problems: partial or complete obstructions, decreased motility like paralytic ileus, subjects at risk of gastric retention
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Solifenacin succinateAlso: solifenacin, YM905, solifenacin succinate suspensionOral suspension | Drug | Solifenacin succinate |
Primary outcome
Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC)
Time frame: Baseline and Week 24
MCC was the volume instilled into the bladder prior to leakage or end of bladder-filling (whichever was reached first), as assessed by urodynamics (procedure: the bladder was to be filled until voiding/leakage began, or until it was stopped because either the participant experienced pain or discomfort or 135% of expected bladder capacity [EBC] was reached for participants ≥ 2 years or of maximum catheterized volume [MCV] for participants aged 6 months to < 2 years; the participants' bladder was emptied via catheterization).
41 secondary outcomes
Change From Baseline to Weeks 3, 6, 9, 12 and 52 in MCC
Time frame: Baseline and Weeks 3, 6, 9, 12, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Compliance
Time frame: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Detrusor Pressure at End of Bladder-Filling
Time frame: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Detrusor Pressure 5 Minutes After End of Bladder-Filling
Time frame: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Catheterized Volume 5 Minutes After End of Bladder-Filling
Time frame: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume Until First Detrusor Contraction (> 15 cmH2O)
Time frame: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 10 cmH20 Detrusor Pressure
Time frame: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 20 cmH20 Detrusor Pressure
Time frame: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 30 cmH20 Detrusor Pressure
Time frame: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Number of Overactive Detrusor Contractions (> 15 cmH2O) Until Leakage or End of Bladder-Filling
Time frame: Baseline and Weeks 3, 6, 9, 12, 24, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Average Catheterized Volume Per Catheterization
Time frame: Baseline and Weeks 3, 6, 9, 12, 24, 36, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Maximum Catheterized Volume (MCV)
Time frame: Baseline and Weeks 3, 6, 9, 12, 24, 36, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Average First Morning Catheterized Volume
Time frame: Baseline and Weeks 3, 6, 9, 12, 24, 36, 52
Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Mean Number of Periods Between the Clean Intermittent Catheterizations (CICs) With Incontinence Per 24 Hours
Time frame: Baseline and Weeks 3, 6, 9, 12, 24, 36, 52
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day at Baseline
Time frame: 3 days prior to Baseline visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 3
Time frame: 3 days prior to Week 3 visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 6
Time frame: 3 days prior to Week 6 visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 9
Time frame: 3 days prior to Week 9 visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 12
Time frame: 3 days prior to Week 12 visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 24
Time frame: 3 days prior to Week 24 visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 36
Time frame: 3 days prior to Week 36 visit
Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 52
Time frame: 3 days prior to Week 52 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day at Baseline
Time frame: 3 days prior to Baseline visit
Percentage of Days With of Incontinence for Each Hour of 24 Hour Day During Week 3
Time frame: 3 days prior to Week 3 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 6
Time frame: 3 days prior to Week 6 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 9
Time frame: 3 days prior to Week 9 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 12
Time frame: 3 days prior to Week 12 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 24
Time frame: 3 days prior to Week 24 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 36
Time frame: 3 days prior to Week 36 visit
Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 52
Time frame: 3 days prior to Week 52 visit
Change From Baseline to Week 24 and 52 in Infant and Toddler Quality of Life Short Form-47 Questionnaire (ITQoL SF-47) - Overall Health Score
Time frame: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Physical Abilities Score
Time frame: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Growth and Development Score
Time frame: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Pain Score
Time frame: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Temperament and Moods Score
Time frame: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Behaviour Score
Time frame: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - General Health Score
Time frame: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Change in Health Score
Time frame: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Parent-Emotional Impact Score
Time frame: Baseline and Weeks 24, 52
Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Parent-Time Impact Score
Time frame: Baseline and Weeks 24, 52
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 33231929Tannenbaum S, den Adel M, Krauwinkel W, Meijer J, Hollestein-Havelaar A, Verheggen F, Newgreen D. Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity. Pharmacol Res Perspect. 2020 Dec;8(6):e00684. doi: 10.1002/prp2.684.
- Derived from this study: PubMed 32007426Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E, Snijder R, Stroosma O, Verheggen F, Newgreen D, Bosman B, Vande Walle J. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies. J Pediatr Urol. 2020 Apr;16(2):180.e1-180.e8. doi: 10.1016/j.jpurol.2019.12.012. Epub 2019 Dec 27.
- Individual participant dataSharing planned: No. Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Related trials for Neurogenic Detrusor Overactivity
Recruiting
Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury
Spinal Cord Injury, Acute
RecruitingPhase 1/2
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
Neurogenic Detrusor Overactivity, Spinal Cord Injuries
Not yet recruiting
TTNS in SCI Patients With Neurogenic Detrusor Overactivity
Spinal Cord Injuries, Neurogenic Detrusor Overactivity
Not yet recruitingObservational study
The Predictive Value of Lower Extremity Hypertonia on Neurogenic Detrusor Overactivity After Spinal Cord Injury
Spinal Cord Injuries (SCI)
Not yet recruitingPhase 1/2
Device for Bladder Control for Men With SCI
Neurogenic Bladder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director study director
Astellas Pharma Europe B.V.
8 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Solifenacin succinate in people with Neurogenic Detrusor Overactivity and Pediatric, run by Astellas Pharma Europe B.V. at 8 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in Poland, South Korea, United States, Belgium, Philippines and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 21 Jun 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC) (time frame: Baseline and Week 24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01981954, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2024.